Targeted Therapy for Hepatocellular Carcinoma

详细信息    查看全文

• 作者：Nitin Ohri ; MD^* ; Andreas Kaubisch ; MD^&dagger ; ; Madhur Garg ; MD^* ; Chandan Guha ; MD ; PhD^* ; ^{cguhamd@gmail.com" class="auth_mail" title="E-mail the corresponding author}
• 刊名：Seminars in Radiation Oncology
• 出版年：2016
• 出版时间：October 2016
• 年：2016
• 卷：26
• 期：4
• 页码：338-343
• 全文大小：205 K

文摘

Hepatocellular cancer (HCC) is a leading cause of cancer death worldwide, and most patients who are diagnosed with HCC are ineligible for curative local therapy. The targeted agent sorafenib provides modest survival benefits in the setting of advanced disease. Novel systemic treatment options for HCC are sorely needed. In this review, we identify and categorize the drugs and targets that are in various phases of testing for use against HCC. We also focus on the potential for combining these agents with radiotherapy. This would help identify directions for future study that are likely to yield positive findings and improve outcomes for patients with HCC.